Teva Pharmaceutical Industries Ltd.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B | $16.89B | $18.27B |
| Cost of Revenue | $8.32B | $8.48B | $8.20B | $7.95B | $8.28B | $8.93B | $9.35B | $9.98B |
| Gross Profit | $8.94B | $8.06B | $7.65B | $6.97B | $7.59B | $7.73B | $7.54B | $8.30B |
| Gross Margin | 51.8% | 48.7% | 48.2% | 46.7% | 47.8% | 46.4% | 44.6% | 45.4% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | $98.0M | — | — | — | $114.0M |
| SG&A Expense | $1.29B | $1.16B | $1.16B | $1.18B | $1.10B | $1.17B | $1.19B | $1.30B |
| Operating Income | $2.16B | $-303.0M | $433.0M | $-2.20B | $1.72B | $-3.57B | $-443.0M | $-1.64B |
| Operating Margin | 12.5% | -1.8% | 2.7% | -14.7% | 10.8% | -21.4% | -2.6% | -9.0% |
| Interest Expense | $916.0M | $1.00B | $1.03B | $930.0M | $891.0M | $901.0M | $822.0M | $920.0M |
| Pretax Income | $1.22B | $-1.28B | $-624.0M | $-3.16B | $658.0M | $-4.41B | $-1.27B | $-2.60B |
| Income Tax Expense | $-180.0M | $676.0M | $-7.0M | $-643.0M | $211.0M | $-168.0M | $-278.0M | $-195.0M |
| Net Income | $1.41B | $-1.64B | $-559.0M | $-2.45B | $417.0M | $-3.99B | $-999.0M | $-2.15B |
| Net Margin | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% | -24.0% | -5.9% | -11.8% |
| EPS (Basic) | $1.23 | $-1.45 | $-0.50 | $-2.20 | $0.38 | $-3.64 | $-0.91 | $-2.35 |
| EPS (Diluted) | $1.21 | $-1.45 | $-0.50 | $-2.20 | $0.38 | $-3.64 | $-0.91 | $-2.35 |
| Shares Outstanding (Basic) | 1.15B | 1.13B | 1.12B | 1.11B | 1.10B | 1.10B | 1.09B | 1.02B |
| Shares Outstanding (Diluted) | 1.16B | 1.13B | 1.12B | 1.11B | 1.11B | 1.10B | 1.09B | 1.02B |
| Dividends Per Share | — | — | — | — | — | — | $0.00 | $0.00 |